In vivo, BPT567 is well tolerated, induces expansion of effector memory CD8 T cells, and exhibits strong anti-tumor efficacy at significantly lower IL-18 doses compared to the combination of an untargeted antibody-IL-18 conjugate and an anti-PD1 antibody further substantiating the importance of cis-signaling. Here, CD8A is linked to neoplasm.